PrP^C controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.

ABSTRACT: Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized. We hypothesized that the cellular prion protein PrP^C could be involved in EMT and EGFR-TKI resistance in NSCLC. Using 5 independent lung adenocarcinoma datasets, including our own cohort, we document that the expression of the PRNP gene encoding PrP^C is associated with EMT. By manipulating the levels of PrP^C in different EGFR-mutated NSCLC cell lines, w

SUBMITTER: Lailler C 

PROVIDER: S-EPMC11379626 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature